Antibodies
23 October 2014
ABLYNX’S ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE DEMONSTRATES A BIOAVAILABILITY OF MORE THAN 80% AFTER SUBCUTANEOUS INJECTION21 October 2014
MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company’s Lead Clinical Development Candidate20 October 2014
Sanofi : Sanofi and Regeneron Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis17 October 2014
AbGenomics Announces IND Filing for AbGn-168H (Neihulizumab) to Treat Psoriatic Arthritis12 October 2014
Janssen Submits Application Seeking Approval Of STELARA® In European Union For Pediatric Plaque Psoriasis10 October 2014
Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patients10 October 2014
Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia10 October 2014
Sobi’s collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe9 October 2014
XOMA Launches XOMA 358 Clinical Development9 October 2014
Positive results from Phase IIb benralizumab study in severe asthma published in The Lancet Respiratory Medicine7 October 2014
EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)3 October 2014
Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic EsophagitisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports